AbstractBySubCategory

Multidisciplinary Treatment

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

2017 Gastrointestinal Cancers Symposium

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
A randomized phase II study of individualized stereotactic body radiation therapy (SBRT) versus transarterial chemoembolization (TACE) with DEBDOX beads as a bridge to transplant in hepatocellular carcinoma (HCC). Francis W. Nugent

223

Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. Julien Edeline

225

Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study. Ignacio Melero

226

Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET). Jennifer A. Chan

228

A phase Ib/II pilot trial with nab-paclitaxel plus gemcitabine plus cisplatin in patients (pts) with stage IV pancreatic cancer. Gayle S. Jameson

341

A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (PDAC). Philippa Corrie

342

Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) + capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2). Herbert Hurwitz

343

Outcomes with sorafenib (SOR) followed by regorafenib (REG) or placebo (PBO) for hepatocellular carcinoma (HCC): Results of the international, randomized phase 3 RESORCE trial. Richard S. Finn

344

Results from a phase 2b, randomized, multicenter study of GVAX pancreas and CRS-207 compared to chemotherapy in adults with previously-treated metastatic pancreatic adenocarcinoma (ECLIPSE Study). Dung T. Le

345

Adjuvant chemoradiation for node-positive pancreatic adenocarcinoma: A propensity-matched analysis. Mustafa Raoof

347

Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial. Jonathan R. Strosberg

348

Significant upstaging of patients with stage I pancreatic cancer from clinical to pathologic staging. Heather Stuart

349

Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma: A GERCOR randomized phase II study (AFUGEM). Olivier Dubreuil

350

Two-stage hepatectomy for colorectal liver metastases: A multi-institutional retrospective review. Nicholas G Berger

351

Actual 5-year survivors following resection of hilar cholangiocarcinoma. Thuy Tran

352

Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. Joseph Junyong Park

353

Development and validation of a prognostic nomogram and score to predict overall survival and usefulness of second-line chemotherapy in advanced pancreatic adenocarcinoma. Angélique Vienot

354

Impact of timing of adjuvant chemotherapy initiation on survival in pancreatic adenocarcinoma. Sofia Palacio

355

Histologic classification and grading enhances gallbladder cancer staging: A population-based prognostic score validated by the U.S. Extrahepatic Biliary Malignancy Consortium. Thuy Tran

356

Hepatocellular carcinoma (HCC): Resection with adjuvant hepatic artery infusion chemotherapy (HAIC) versus resection alone—A systematic review and meta-analysis. Alexandra Moran

357

Interim results of a multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC). Jill Lacy

358

Initial gemcitabine/nab-paclitaxel (GA) followed by sequential (S) mFOLFIRINOX or alternating (A) mFOLFIRI in metastatic pancreatic cancer (mPC): The SEENA-1 study. Vincent J. Picozzi

359

Analysis of the effect of adjuvant therapy on overall survival for resected gallbladder adenocarcinoma using the National Cancer Database. David G. Brauer

360

Neoadjuvant therapy versus upfront surgery for pancreatic adenocarcinoma: A propensity score matched analysis of short-term outcomes. Gyulnara G. Kasumova

361

A phase 1b/2 study of INCB039110 + nab-paclitaxel (N) and gemcitabine (G) in patients (pts) with advanced solid tumors and pancreatic cancer (PC). Gregory Lawrence Beatty

362

Updated results of a phase 1 study combining the matrix metalloproteinase 9 inhibitor GS-5745 with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer. Johanna C. Bendell

363

Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC). Vincent J. Picozzi

365

Comparison of outcomes in patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy (SBRT) versus conventionally fractionated radiation: An analysis of the National Cancer Database. Jim Zhong

366

Curative treatment in gallbladder cancer: Adjuvant or multimodal concepts—Evidence from data of 975 cases of The German Registry of Incidental Gallbladder Carcinoma. Thorsten Oliver Goetze

367

FOLFIRINOX (F-NOX) followed by individualized radiation for borderline-resectable pancreatic cancer: Preliminary toxicity and R0 resection rates from a prospective phase II study. Janet E. Murphy

368

Evaluating associations of diabetes, insulin use, and BMI with efficacy in patients with resected pancreatic cancer: An ancillary analysis of NRG Oncology/RTOG 9704. Theodore S. Hong

369

Necuparanib combined with nab-paclitaxel + gemcitabine in patients with metastatic pancreatic cancer: Phase 2 results. Eileen Mary O'Reilly

370

Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey. Takashi Kokudo

371

Dose escalation in locally advanced pancreatic cancer patients receiving chemoradiotherapy. Seung Yeun Chung

372

Adjuvant therapy (AT) following resection of pancreatic ductal adenocarcinoma (PDAC): Are patients from rural, remote areas disadvantaged? Kimberly A Bertens

373

Exposure-response (ER) relationship of regorafenib (REG) in patients with hepatocellular carcinoma (HCC). Alexander Solms

374

Prognostic significance of chromogranin A in small pancreatic neuroendocrine tumors. Mustafa Raoof

375

A propensity-matched analysis of laparoscopic versus open distal pancreatectomy for pancreatic adenocarcinoma. Mustafa Raoof

376

Role of aggressive surgical debulking in older adults with gastrointestinal neuroendocrine tumors. Zeljka Jutric

377

Efficacy of lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in patients with neuroendocrine tumor (NET) previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III ELECT study. Rodney F. Pommier

378

A phase IB, multicenter, open-label study to assess the safety, tolerability, and efficacy of the pleiotropic pathway modifier CC122 administered orally to patients with advanced HCC. Robin Kate Kelley

379

The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors. Eric Raymond

380

Propensity score matched analysis of neoadjuvant therapy for resectable pancreatic cancer. Kenneth L Meredith

381

A nomogram to predict pathologic lymph node positivity in clinical stage I-II pancreatic adenocarcinoma. Douglas S. Swords

382

Survival analysis of yttrium-90 radioembolization for unresectable intrahepatic cholangiocarcinoma. Alexandra Gangi

383

A phase I study of mFOLFOX6 and ADI-PEG-20 in patients (pts) with advanced hepatocellular carcinoma (HCC) and other gastrointestinal (GI) malignancies. James J. Harding

384

Up-titration of sorafenib for hepatocellular carcinoma: Impact on duration of exposure and cost. David Edward Kaplan

385

TGF-B1 inhibition with losartan in combination with FOLFIRINOX (F-NOX) in locally advanced pancreatic cancer (LAPC): Preliminary feasibility and R0 resection rates from a prospective phase II study. Janet E. Murphy

386

Treatment patterns of gastrointestinal neuroendocrine tumors (NET). Michael S. Broder

387

Survival outcomes of adjuvant chemotherapy combined with radiation versus chemotherapy alone following pancreatectomy for distal pancreatic adenocarcinoma: Single institution experience. Bhavina D O Batukbhai

388

Proton beam therapy for liver cancer is well tolerated: Outcomes from the Proton Collaborative Group REG001-09 trial. Michael David Chuong

389

Clinical implication of inflammation-based prognostic score and perioperative nutrition control in pancreatic cancer. Nao Takano

390

Impact of adjuvant therapies on treatment outcomes for patients with resected gallbladder cancer and changes in treatment patterns in the United States over the past decade: An analysis from the National Cancer Data Base. Timur Mitin

391

Gemcitabine/taxane adjuvant therapy in resected pancreatic cancer: A signal of improved survival? Zaheer S Kanji

392

Interim analysis of perioperative modified FOLFIRINOX (mFOLFIRINOX) in resectable pancreatic cancer (PC). Michael Cecchini

393

Outcomes of FOLFIRINOX (FFX) and gemcitabine+nab-paclitaxel (GnP) in initially unresectable locally advanced pancreatic cancer (uLAPC): A population-based study. Kelvin K. Chan

394

Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high-volume referral centre. Malinda Itchins

395

Nab-paclitaxel (Nab-P) and gemcitabine (G) first-line chemotherapy (CT) in patients (pts) with metastatic pancreatic cancer (mPC) who relapsed after adjuvant treatment (ADJ T): A “REAL LIFE” study. Guido Giordano

396

Treatment patterns among patients with metastatic GEP-NET treated at a tertiary referral center. Jessica J Jalbert

397

Safety and tolerability of lanreotide autogel/depot (LAN) in patients (pts) with neuroendocrine tumors (NETs): Pooled analysis of clinical studies. Alexandria T. Phan

398

Phase 1b study with PEGylated human IL-10 (AM0010) with 5-FU and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC). J. Randolph Hecht

399

The effect of sorafenib (S) starting dose and dose intensity on survival in patients with advanced hepatocellular carcinoma (HCC). Mohammed Abdullah Alghamdi

400

Pancreatic neuroendocrine tumors: A population-based analysis of epidemiology and outcomes. Samer Alsidawi

401

Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway. Milind M. Javle

402

Safety and efficacy of accelerated hypofractionation and stereotactic body radiotherapy for hepatocellular carcinoma in the setting of advanced liver dysfunction. Nima Nabavizadeh

403

Sorafenib for hepatocellular carcinoma managed by non-oncologists: Impact on drug exposure and survival. David Edward Kaplan

404

Effectiveness and safety of sorafenib for unresectable and advanced intrahepatic cholangiocarcinoma: A pilot study. Xiangji Luo

405

Characteristics of intrahepatic cholangiocarcinoma according to tumor location. Mitsuo Shimada

406

Impact of duodenal invasion on outcomes in patients with pancreatic cancer treated with stereotactic body radiotherapy. Gilbert Murimwa

408

Clinical and molecular determinants of treatment benefit with phase I trials in patients (pts) with advanced pancreatic cancer (PC). Helena Verdaguer

409

A phase I/II study combining tosedostat with capecitabine in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Andrea Wang-Gillam

410

Survival difference among patients with hepatocelluar carcinoma (HCC) based on stage of disease: The pre- and post-sorafenib era. Chintan Shah

411

Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) ± gemcitabine (Gem) in solid tumors: Interim results from the pancreatic cancer (PC) cohorts. Zev A. Wainberg

412

Health care costs and treatment patterns among metastatic pancreatic cancer (MPC) patients (pts) initiating first-line (1L) on nab-paclitaxel/gemcitabine (nab-P+G) or FOLFIRINOX (FFX). Ali McBride

415

Usefulness of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy to predict prognosis of advanced biliary tract cancer. Kyoung Min Cho

416

A phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer. Nai-Jung Chiang

417

Frailty: A major consideration for short- and long-term outcomes in resected pancreatic cancer. Ioannis Konstantinidis

418

The relationship between antitumor effects and relative dose intensity of gemcitabine plus nab-paclitaxel for unresectable pancreatic cancer. Kazunaga Ishigaki

419

Outcomes of second line treatment in patients with advanced and metastatic biliary cancers. Gustavo Figueiredo Marcondes Westin

420

Primary care vs. oncology-driven surveillance following adjuvant chemotherapy in resected pancreas cancer. Haider H Samawi

421

Escalated dose somatostatin analogues (SSAs) in management of neuroendocrine tumors (NETs): A systematic review. David Chan

422

Utility of endoscopic ultrasound-guided biopsy for genomic analysis of pancreatic exocrine malignancies. Brent K Larson

423

Prognostic factors in patients (pts) with advanced biliary tract cancer (BTC) treated with first-line gemcitabine plus cisplatin (GEMCIS): Retrospective analysis of 740 pts. Hyungwoo Cho

424

Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary cancer after failure of gemcitabine plus cisplatin: Retrospective analysis of 321 patients. Jihoon Kang

425

Sequential treatment in patients with metastatic pancreatic neuroendocrine tumors after progression on first-line therapy. Erica S Tsang

426

A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX (mFOLFIRINOX) in previously untreated patients (pts) with advanced gastrointestinal malignancies. Manish Sharma

427

Risk factors associated with recurrent cholangitis in pancreatic and hepatobiliary cancers. Apurva Jain

428

Randomized phase II study of S-1 monotherapy versus gemcitabine plus S-1 in gemcitabine-refractory advanced pancreatic cancer. Makoto Ueno

429

Minimally invasive hepatectomy conversions: An analysis of outcomes. Jack P Silva

430

Identification of educational gaps among oncologists who treat patients with pancreatic cancer. Justin A Barnes

431

A phase II study of combretastatin A4-phosphate (CA4P) in the treatment of well-differentiated, low- to intermediate-grade, unresectable, recurrent, or metastatic pancreatic, or GI neuroendocrine tumors/carcinoid (GI-NETs/PNETs) with elevated biomarkers. Steven K. Libutti

432

Establishment of disease-specific graded prognostic assessment for patients with hepatocellular carcinoma and spinal metastasis. Chai Hong Rim

433

Biweekly cisplatin (C) and gemcitabine (G) in patients (pts) with advanced biliary tract cancer (ABTC): A retrospective analysis. Daniel H. Ahn

434

Discharge to a skilled nursing facility as the strongest modifiable risk factor for readmissions following pancreaticoduodenectomy. Katelin Anne Mirkin

435

Stereotactic body radiotherapy for pancreatic cancer: Analysis of toxicity. Subha Perni

436

The effects of resident participation on patient morbidity and mortality in major gastrointestinal oncologic surgery. Geoffrey Bellini

437

Clinical outcome of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel as first line chemotherapy in metastatic pancreatic cancer. Kazuo Watanabe

438

A phase 1b study of ruxolitinib (Rux) + gemcitabine (G) ± nab-paclitaxel (N) in patients (pts) with advanced solid tumors. Todd Michael Bauer

439

Inverse probability of treatment weighting analysis of upfront surgery versus neoadjuvant chemoradiotherapy followed by surgery for pancreatic adenocarcinoma with arterial abutment. Tsutomu Fujii

440

Should functional renal scans be obtained prior to upper abdominal radiation for pancreatic cancer? Grace Blitzer

442

Surgical intervention in early-stage pancreatic adenocarcinoma. Javaneh Jabbari

443

Correlation of circulating IL-8 levels with improved overall survival in advanced pancreatic cancer patients in response to antisense OT-101 (trabedersen) therapy. Vuong N. Trieu

444

Activity of RX-3117, an oral antimetabolite nucleoside, in patients with pancreatic cancer: Preliminary results of stage 1 of the phase 1a/2b. Drew W. Rasco

445

Ovarian metastasis from midgut neuroendocrine tumors: Incidence, clinical implications, and management options—An update. Aman Chauhan

446

Does hepatectomy approach influence transfusion? An analysis of the National Surgical Quality Improvement Program database. Jack P Silva

447

Management of recurrent pancreatic cancer after surgical resection: Systematic review, evidence mapping, and meta-analysis. Jong-Chan Lee

448

Efficacy of S-1 compared to modified FOLFIRINOX as second-line chemotherapy regimens after gemcitabine plus nab-paclitaxel for patients with metastatic pancreatic cancer. Gen Kimura

449

Optimal indications for chemotherapy in elderly patients with unresectable pancreatic cancer. Shoichi Nakazuru

450

Small bowel adenocarcinoma treatment: A single centre experience. Philip Bredin

451

Consensus treatment guidelines for urgent symptoms in cholangiocarcinoma (CC) patients (pts) with biliary stents or catheters using the modified RAND/UCLA Delphi process. Renuka V. Iyer

452

The effect of duloxetine on chemotherapy-induced peripheral neuropathy in advanced pancreatic cancer patients receiving gemcitabine plus nab-paclitaxel treatment. Hidetaka Suzuki

453

Surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: Meta-analysis of randomized controlled trials. Kyung-Hun Lee

454

Can total psoas area predict toxicity after stereotactic body radiation therapy in borderline resectable and locally advanced pancreatic cancers? Will Jin

455

Clinical outcomes of early-stage ampullary carcinoma: A single institutional experience. Ashish Manne

456

Role of lymph node dissection for intrahepatic cholangiocarcinoma. Taizo Hibi

457

Analysis of outcomes in metastatic pancreatic cancer: Real-world experience in academic cancer centers. Elizabeta C. Popa

458

Characteristics and treatment patterns of elderly patients with biliary tract cancers. Ji Hyun Yang

459

Skeletal muscle depletion to predict survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy. Kyoung Min Cho

460

A single institutional experience of carbon-ion radiotherapy for locally advanced pancreatic cancer. Makoto Shinoto

461

The phase I study of concurrent chemoradiotherapy using a combination of gemcitabine and nab-paclitaxel for unresectable locally advanced pancreatic cancer: Update. Tatsuya Ioka

462

Platelet-to-hemoglobin ratio to predict progression-free survival for patients with locally advanced hepatocellular carcinoma. Xing Li

463

FDG PET/CT in pancreatic cancer staging and management: A retrospective study. Ana Beatriz Kinupe Abrahao

464

Cancer of unknown primary (CUP) with disseminated-lymphadenopathy presentation: Clinicopathological features, prognostic factors, and survival outcomes. Kanwal Pratap Singh Raghav

465

Efficacy of chemotherapy in patients with recurrent pancreatic cancer. Akihiro Ohba

466

Modified FOLFIRINOX for metastatic pancreatic adenocarcinoma after failure of nab-paclitaxel plus gemcitabine. Masato Ozaka

467

Determinants of first-line treatment selection in advanced pancreatic ductal adenocarcinoma (PDAC). Hui-Li Wong

468

Preliminary analysis of FOLFIRI regimen with or without bevacizumab as second-line systemic therapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma. Xiaoying Zhao

469

The short- and long-term outcomes of pancreatic resection for pancreatic adenocarcinoma in patients older than 75 years. Keisuke Kazama

470

An open-label, single-group, multicenter phase II study of lanreotide autogel (LAN) in Japanese patients (pts) with neuroendocrine tumors (NET). Tetsuhide Ito

471

The surgical Apgar score is an independent prognostic factor in patients with pancreatic cancer undergoing pancreaticoduodenectomy followed by adjuvant chemotherapy. Yosuke Atsumi

472

Neoadjuvant FOLFIRINOX and/or gemcitabine/nab-paclitaxel for advanced pancreatic adenocarcinoma. Keli Turner

473

The utilization of palliative radiation therapy to the liver for hepatocellular carcinoma. Sara-Jane N. Onyeama

474

The efficacy of first-line chemotherapy in recurrent pancreatic cancer after S-1 adjuvant chemotherapy. Ryo Kanata

475

A phase II study of gemcitabine, erlotinib, and S-1 in patients with advanced pancreatic cancer. Boram Han

476

Premorbid body mass and mortality in patients with hepatocellular cancer: A systematic review and meta-analysis. Arjun Gupta

477

Incidence of venous thromboembolic events following major pelvic and abdominal surgery for cancer. Pablo Emilio Serrano Aybar

478

Sorafenib treatment in recurrent hepatocellular carcinoma post liver transplantation. Nazanin Fallah-Rad

479

Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience. Jongchan Lee

480

Patterns of treatment outcomes in older patients with metastatic pancreatic cancer. Hyun Ae Jung

481

Phase II study of first-line radioembolization with yttrium-90 glass microspheres for intrahepatic cholangiocarcinoma. Ravi Shridhar

482

Impact of nab-paclitaxel-based second-line chemotherapy on the outcomes of pancreatic cancer. Neelakanta Dadi

483

Modified FOLFIRINOX regimen in advanced biliary tract adenocarcinoma. Amit Rauthan

484

The efficacy and safety of gemcitabine + nab-PTX for recurrence and refractory pancreatic cancer. Kei Saito

485

Surgical management of pancreatic cancer at a regional health system. Aaron Chevinsky

486

Adjuvant stereotactic body radiotherapy (SBRT) for resected primary and metastatic liver cancers. Latifa Bazzi

487

Frequency of severe neutropenia occurring as an adverse events of gemcitabine plus cisplatin chemotherapy in patients with recurrent biliary tract cancer compared to those with unresectable biliary tract cancer. Noriko Fujishiro

488

Is gemcitabine effective for pancreatic cancer after progression to FOLFIRINOX? Bruno Melo Fernandes

489

Palliative chemotherapy and travel distance impacts hospice referral in patients with stage IV pancreatic cancer. Jennifer Michelle Duff

490

Assessment of the incidence of medical events reported following Y90 treatment. Petra Prins

491

Gemcitabine and S-1 as first-line chemotherapy in patients with metastatic or advanced pancreatic cancer. Weijia Fang

492

Stereotactic body radiotherapy for hepatocellular carcinoma in the setting of poor liver function: A case series. Vladimir Valakh

493

Clinical outcomes in borderline resectable pancreatic cancer: A cohort study. Davendra Sohal

494

The Charlson age comorbidity index to predict prognosis in patients with resected pancreatic cancer. Tomonari Asano

495

Sorafenib treatment for advanced hepatocellular carcinoma: Effectiveness, safety, and controversial points. Takayoshi Oikawa

496

Nab-paclitaxel and gemcitabine in advanced pancreatic cancer: The one-year experience of the National Cancer Institute of Naples. Alessandro Ottaiano

497

Gemcitabine plus nab-paclitaxel use in metastatic pancreatic cancer: A study of 40 patients. Ivan Barrera

498

Borderline resectable pancreas adenocarcinoma managed with neoadjuvant chemoradiotherapy: A prospective case series. Hiren A. Mandaliya

499

KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma. Richard S. Finn

TPS503

KEYNOTE-224: Phase II study of pembrolizumab in patients with previously treated advanced hepatocellular carcinoma. Andrew X. Zhu

TPS504

Phase I study of defactinib combined with pembrolizumab and gemcitabine in advanced cancer. Andrea Wang-Gillam

TPS505

A randomized controlled trial to compare the effectiveness between surgery and radiofrequency ablation for hepatocellular carcinoma: SURF trial. Kiyoshi Hasegawa

TPS506

A phase II multicenter study evaluating combination immunotherapy with pembrolizumab and peginterferon alfa-2b for advanced cholangiocarcinoma. Aiwu Ruth He

TPS507

SWOG S1505: A randomized phase II study of perioperative mFOLFIRINOX vs. gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinom. Davendra Sohal

TPS508

Gemcitabine and cisplatin plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase II trial. Ashwin Reddy Sama

TPS509

Phase Ib/II study of ALT-803 in combination with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer. Jared David Acoba

TPS510

A phase II pilot trial of nivolumab + albumin bound paclitaxel + paricalcitol + cisplatin + gemcitabine (NAPPCG) in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinoma. Erkut Hasan Borazanci

TPS511

Phase I study of definitive chemoradiation with gemcitabine and the WEE1 inhibitor AZD1775 in unresectable pancreatic cancer. Kyle Clifford Cuneo

TPS512

A phase II trial of escalated dose proton radiotherapy with elective nodal irradiation and concomitant chemotherapy for patients with unresectable, borderline resectable, or medically inoperable pancreatic adenocarcinoma. Romaine Charles Nichols

TPS513

A single arm, prospective multicenter phase II study FOLFIRINOX in patients with advanced and recurrent biliary tract cancer. Naminatsu Takahara

TPS514

Phase I/IB multicenter study of afatinib in combination with capecitabine in patients (pts) with refractory solid tumors and pancreatico-biliary cancers. Amy E. Chang

TPS515

A phase II trial of neoadjuvant chemotherapy with GSL (GEM+TS-1+LV) for marginally resectable pancreatic cancer. Yoshihiro Sakamoto

TPS516

5-fluorouracil, oxaliplatin and dasatinib (FOLFOX-D) for previously untreated metastatic pancreatic adenocarcinoma. Thomas J. George

TPS517

A pilot-blinded randomized feasibility trial comparing an investigational hand therapy intervention (IHT) to a traditional occupational therapy (TOT) intervention to prevent chemotherapy induced peripheral neuropathy (CIPN) of the hands in patients (pts) receiving chemotherapy (CTX). Gayle S. Jameson

TPS518